TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04517591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Take a STAND for health
Description: A 4-month parallel-group randomised controlled trial will be performed, in which patients post-bariatric surgery will be assessed at baseline pre-surgery (PRE-BAR), 3 months after surgery and pre-intervention (PRE-INT) and 4 months after intervention (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.
Study: NCT01369355

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo will be administered subcutaneously.
Study: NCT03935295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: Paraspinal abobotulinumtoxinA injections (compared to placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo prepared by Ipsen for use as control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Thoracolumbosacral Orthosis
Description: Non-operative external bracing for scoliosis curves
Study: NCT01369355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Placebo will be administered as a single Intravenous infusion at week 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg SC q8w
Description: Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg SC q8w
Description: Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 130 mg IV
Description: Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg SC q12w
Description: Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg SC q12w
Description: Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
Study: NCT00592748

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Charged Particle Radiation Therapy
Description: Radiation doses will be determined by planning CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Charged Particle Radiation Therapy
Description: Radiation doses will be determined by planning CT
Study: NCT00747279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restrictive strategy
Description: Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
Study: NCT03935295

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Custom Thoracolumbosacral Orthosis
Description: Non-operative external bracing for scoliosis curves
Study: NCT00747279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive insulin therapy
Description: Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
Study: NCT00558753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
Study: NCT00257816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: (First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
Study: NCT03599115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibitory Control Training
Description: Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inhibitory Control Training
Description: Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).
Study: NCT03472872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1,000mg acetaminophen IVPB
Study: NCT03576989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA+DHA
Description: EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo contains mineral oil
Study: NCT05233631

Intervention type: PROCEDURE
Intervention: Therapeutic Endoscopic ultrasound
Description: A minimally invasive procedure to assess digestive (gastrointestinal) and lung diseases. Procedure allows detailed imaging of the regional anatomy by approximating the frequency transducer to the region of interest.
Study: NCT03930199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Needs-based intervention (physical, psychological, or both)
Description: Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
Study: NCT04333576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Tablet:Oral
Study: NCT01985724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte-colony stimulating growth factor
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating growth factor
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
Study: NCT02051660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualized CALM intervention
Description: Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-manualized supportive intervention.
Description: Supportive psycho-oncological intervention.
Study: NCT04333576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Tablet:Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix
Description: Tablet:Oral
Study: NCT04066998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tears sampling
Description: Tears sampling
Study: NCT04333576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive
Description: Tablet:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive
Description: Tablet:Oral
Study: NCT04066998

Intervention type: OTHER
Group type: OTHER
Intervention: Tears sampling
Description: Tears sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lashes sampling
Description: Lashes sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Lashes sampling
Description: Lashes sampling
Study: NCT04333576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined Oral Contraceptive
Description: Tablet:Oral
Study: NCT03890757

Intervention type: OTHER
Intervention: ultrasound guided paravertebral or serratus anterior block
Description: Patients groups will be as follow:~Group (I): Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe ,Group (II): thoracic paravertebral block will be performed in the sitting position. The spinal level chosen for needle insertion will be two segments below the upper most fractured rib or midway between the upper most and lowest fractured rib, 2-2.5 cm distance from the midline in the same injury site
Study: NCT02018614

Intervention type: OTHER
Intervention: algoplus

Intervention type: OTHER
Intervention: algoplus
Study: NCT05941611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Description: Oral-B powered toothbrush
Study: NCT03208517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme
Description: The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
Study: NCT01563627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling for drug resistance biomarkers
Description: comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling for drug resistance biomarkers
Description: comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study: NCT01104103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BOA(R)-Constricting IV Band
Description: Device applied in accordance with manufacturer's instructions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard elastic constricting band
Description: Standard therapy
Study: NCT00577447

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid (DHA)
Description: Capsule containing 200mg of DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule containing corn and soybean oil
Study: NCT00578695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixivaptan
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT02309840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choice architecture
Description: 1. Place vegetables at the beginning of the lunch line.~2. Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~3. Promote fruits and vegetables with prominently displayed signage and images.~4. Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choice architecture
Description: 1. Place vegetables at the beginning of the lunch line.~2. Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~3. Promote fruits and vegetables with prominently displayed signage and images.~4. Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chef-enhanced meals
Description: meals prepared by a professional chef with enhanced palatability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chef-enhanced meals
Description: meals prepared by a professional chef with enhanced palatability
Study: NCT01354938

Intervention type: DRUG
Intervention: Clarithromycin modified release 500 mg
Description: Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
Study: NCT01232049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Oral Dose of
Description: Pitavastatin 4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Oral Dose of
Description: Pitavastatin 4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Oral Dose of
Description: Valsartan 320mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Oral Dose of
Description: Valsartan 320mg
Study: NCT02287636

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo fludeoxyglucose F 18 PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fludeoxyglucose F 18 PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fludeoxyglucose F 18 PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo PET/MRI
Study: NCT03407729

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.

Intervention type: OTHER
Intervention: Cognitive Performance Testing
Description: For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.

Intervention type: OTHER
Intervention: Cognitive Performance Testing
Description: For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
Study: NCT01845753

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT03962868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental procedure : ESD
Description: ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (\<1.5%)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison procedure: WF-piece meal EMR
Description: WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
Study: NCT00070239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorothymidine
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study: NCT00669435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan + Simvastatin
Description: tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine + Simvastatin
Description: tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months
Study: NCT02104258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy ASPETAR
Description: Standardized physiotherapy protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy ASPETAR+
Description: Standardized physiotherapy protocol including early lengthening exercises
Study: NCT01705483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP9853
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP9853
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Taxol
Study: NCT03206151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB009
Description: for injection only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: for injection only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: for injection only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: for injection only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: for injection only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: for injection only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: for injection only
Study: NCT06400238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT01563627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study: NCT02725073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter \[MAJ-1419; Olympus America, Center Valley, Pa., USA\]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research \& Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
Study: NCT00887718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: 18F-Fluorodeoxyglucose (FDG) injection
Study: NCT00287638

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive pressure device with a time clock